● Recruiting

Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases

Condition: Brain Metastases From Non-small Cell Lung Cancer (NSCLC) · Brain Metastases From Melanoma · Brain Metastases From Breast Cancer · Sponsor: The Netherlands Cancer Institute

PhaseNA

Planned participants100

Who can joinAll sexes, N/A to no upper limit

Healthy volunteersNo

About this study

This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Lente Kroon, MD · 0031205129111 · neurologie@nki.nl

Dieta Brandsma, MD, PhD

Always discuss trial participation with your own doctor first.

Locations (1)

Netherlands Cancer Institute - Antoni van Leeuwenhoek

Amsterdam, Netherlands

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07511933